Myeloproliferative Neoplasms: Future Directions in Care
Closing out their discussion on the management of myeloproliferative neoplasms, Rami S. Komrokji, MD, and Pankit Vachhani, MD, look toward the future treatment paradigm.
Transcript:
Rami S. Komrokji, MD:The field had changed going from only hydria and transplant to many options. It's exciting for me to be able to offer my patients more options and choices of therapy and I would like to hear also your thoughts on where the field is going and final closing remarks about this long discussion about the myelofibrosis and new treatments.
Pankit Vachhani, MD: Dr Komrokji we are very fortunate to now have more than one JAK inhibitor therapy in our arsenal. The important point of course is picking the right JAK inhibitor for the right patient, sequencing it, and optimizing the dose and monitoring for toxicities of these JAK inhibitors is very important. I'm personally an advocate for earlier treatment rather than later treatment and clinical trials. When I look at the future and you talked about this very nicely in just the preceding section, the future I see it as one of combination therapies, both in frontline setting as well as in second line setting. And this will be on a JAK1 or JAK1/JAK2, JAK2 inhibitor backbone. They are not going away. In fact, they will have a very central place, but additional mechanism of actions of these newer therapies that you talked about are very exciting and will if not additive or if not synergistic, maybe at least additive effects what we see hopefully. And both in myelofibrosis but also even in PV and ET. The question then that will evolve is- that will come up is how to sequence the therapies, how to combine these therapies and lead to disease modification in MPNs. And we can have a seminar in what that means, but we'll leave it for now and in terms of what disease modification means. Thank you Dr Komrokji. I found this to be very informative. I hope that our audience also found this to be very informative and enjoyable. Dr Komrokji, thank you for your insightful discussion in this section and we hope our audience found this to be of value to the treatment of MPN patients in their planning.
Transcript edited for clarity.
Epcoritamab Delivers Durable Responses in Anthracycline-Ineligible LBCL
December 12th 2024Fixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.
Read More
Lower Cardiac Risks Found With Second-Generation BTK Inhibitors in B-Cell Hematologic Disorders
December 12th 2024In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, overall cardiac adverse events, and heart failure in patients with B-cell hematologic malignancies.
Read More
